Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: Histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520

Human Gene Therapy

Volumn 17, Issue 1, 2006, Pages 55-70

  Bieler, Alexa ^a   Mantwill, Klaus ^a   Dravits, Tanja ^a   Bernshausen, Alexandra ^a   Glockzin, Gabriel ^a   Köhler Vargas, Nadia ^a   Lage, Hermann ^b   Gansbacher, Bernd ^a   Holm, Per S ^a,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Charité Campus Benjamin Franklin Medical Center   (Germany)

^c Xvir Therapeutics   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DL 520; E1A PROTEIN; HISTONE DEACETYLASE INHIBITOR; IRINOTECAN; ONCOLYTIC VIRUS; TRICHOSTATIN A; UNCLASSIFIED DRUG; Y BOX BINDING PROTEIN 1;

ADENOVIRUS; ARTICLE; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; CYTOLYSIS; CYTOPATHOGENIC EFFECT; DRUG EFFICACY; EMBRYO; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN LOCALIZATION; UPREGULATION; VIRAL GENE THERAPY; VIRUS REPLICATION; VIRUS STRAIN;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, SOUTHERN; BRAIN NEOPLASMS; CAMPTOTHECIN; ENZYME INHIBITORS; FIBROBLASTS; GENE DELETION; GENE EXPRESSION; GENTIAN VIOLET; GLIOBLASTOMA; HELA CELLS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; IMMUNOHISTOCHEMISTRY; ONCOLYTIC VIRUSES; PROTEIN SYNTHESIS INHIBITORS; RECEPTORS, VIRUS; TUMOR CELLS, CULTURED;

ADENOVIRIDAE; COXSACKIEVIRUS;

EID: 30744452281     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.17.55     Document Type: Article

References (84)

1. ABE, T., MORI, T., WAKABAYASHI, Y., NAKAGAWA, M., COLE, S.P., KOIKE, K., KUWANO, M., and HORI, S. (1998). Expression of multidrug resistance protein gene in patients with glioma after chemotherapy. J. Neurooncol. 40, 11-18.
2. ASHIZUKA, M., FUKUDA, T., NAKAMURA, T., SHIRASUNA, K., IWAI, K., IZUMI, H., KOHNO, K., KUWANO, M., and UCHIUMI, T. (2002). Novel translational control through an iron-responsive element by interaction of multifunctional protein YB-1 and IRP2. Mol. Cell. Biol. 22, 6375-6383.
3. BABISS, L.E., GINSBERG, H.S., and DARNELL, J.E. (1995). Adenovirus E1B proteins are required for accumulation of late viral mRNA and for effects on cellular mRNA translation and transport. Mol. Cell. Biol. 5, 2552-2558.
4. BARGOU, R.C., JURCHOTT, K., WAGENER, C., BERGMANN, S., METZNER, S., BOMMERT, K., MAPARA, M.Y., WINZER, K.J., DIETEL, M., DORKEN, B., and ROYER, H.D. (1997). Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat. Med. 3, 447-450.
5. BERGELSON, J.M., CUNNINGHAM, J.A., DROGUETT, G., KURT-JONES, E.A., KRITHIVAS, A., HONG, J.S., HORWITZ, M.S., CROWELL, R.L., and FINBERG, R.W. (1997). Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275, 1320-1323.
6. BERK, A.J., and SHARP, P.A. (1978). Structure of the adenovirus 2 early mRNAs. Cell 14, 695-711.
7. BERNT, K.M., STEINWAERDER, D.S., NI, S., LI, Z.Y., ROFFLER, S.R., and LIEBER, A. (2002). Enzyme-activated prodrug therapy enhances tumor-specific replication of adenovirus vectors. Cancer Res. 62, 6089-6098.
8. BROOKS, A., CASHION, L., REITER, K., WANG, P., QIAN, H.S., HARKINS, R.H., HARKINS, R.N., and RUBANYI, G.M. (2003). Histone deacetylase inhibition up-regulates CAR and increases adenovirus infection and transgene expression in skeletal muscle. Mol. Ther. 1(Suppl. 9), 300.
9. BURGER, P.C. (1983). Pathologic anatomy and CT correlations in the glioblastoma multiforme. Appl. Neurophysiol. 46, 180-187.
10. CHAN, H.S., THORNER, P.S., HADDAD, G., and LING, V. (1990). Immunohistochemical detection of P-glycoprotein: Prognostic correlation in soft tissue sarcoma of childhood. J. Clin. Oncol. 8, 689-704.
11. CHAN, H.S., GROGAN, T.M., HADDAD, G., DEBOER, G., and LING, V. (1997). P-glycoprotein expression: Critical determinant in the response to osteosarcoma chemotherapy. J. Natl. Cancer Inst. 89, 1706-1715.
12. CHEON, J., KO, S.C., GARDNER, T.A., SHIRAKAWA, T., GOTOH, A., KAO, C., and CHUNG, L.W. (1997). Chemogene therapy: Osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model. Cancer Gene Ther. 4, 359-365.
13. CHOW, L.T., BROKER, T.R., and LEWIS, J.B. (1979). Complex splicing patterns of RNAs from the early regions of adenovirus-2. J. Mol. Biol. 134, 265-303.
14. DEL VALLE, L., AZIZI, S.A., KRYNSKA, B., ENAM, S., CROUL, S.E., and KHALILI, K. (2000). Reactivation of human neurotropic JC virus expressing oncogenic protein in a recurrent glioblastoma multiforme. Ann. Neurol. 48, 932-936.
15. DIETEL, M., ARPS, H., LAGE, H., and NIENDORF, A. (1990). Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257. Cancer Res. 50, 6100-6106.
16. DION, L.D., GOLDSMITH, K.T., TANG, D.C., ENGLER, J.A., YOSHIDA, M., and GARVER, R.I., Jr. (1997). Amplification of recombinant adenoviral transgene products occurs by inhibition of histone deacetylase. Virology 231, 201-209.
17. DOBNER, T., HORIKOSHI, N., RUBENWOLF, S., and SHENK, T. (1996). Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. Science 272, 1470-1473.
18. FUEYO, J., ALEMANY, R., GOMEZ-MANZANO, C., FULLER, G.N., KHAN, A., CONRAD, C.A., LIU, T.J., JIANG, H., LEMOINE, M.G., SUZUKI, K., SAWAYA, R., CURIEL, D.T., YUNG, W.K.A., and LANG, F.F. (2003). Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J. Natl. Cancer Inst. 95, 652-660.
19. GANLY, I., KIM, Y.T., HANN, B., BALMAIN, A., and BROWN, R. (2001). Replication and cytolysis of an E1B-attenuated adenovirus in drug-resistant ovarian tumour cells is associated with reduced apoptosis. Gene Ther. 8, 369-375.
20. GAUDREAULT, I., GUAY, D., and LEBEL, M. (2004). YB-1 promotes strand separation in vitro of duplex DNA containing either mispaired bases or cisplatin modifications, exhibits endonucleolytic activities and binds several DNA repair proteins. Nucleic Acids Res. 32, 316-327.
21. GOLDSMITH, M.E., KITAZONO, M., FOK, P., AIKOU, T., BATES, S., and FOJO, T. (2003). The histone deacetylase inhibitor FK228 preferentially enhances adenovirus transgene expression in malignant cells. Clin. Cancer Res. 9, 5394-5401.
22. GOODRUM, F.D., and ORNELLES, D.A. (1997). The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle. J. Virol. 71, 548-561.
23. GRAAT, H., WITLOX, M.A., SCHAGEN, F.H.E., KASPERS, G.J.L., CURIEL, D.T., HELDER, M.N., BRAS, J., SCHAAP, G.R., GERRITSEN, W.J., WUISMAN, P.I.J.M., and VAN BEUSECHEM, V.W. (2004). Cisplatin and doxorubicin enhance the activity of the CRAd Ad5-Δ24RGD against osteosarcoma cell lines but not primary osteosarcoma cells. Mol. Ther. 9(Suppl. 1), 110.
24. GRAUMANN, P.L., and MARAHIEL, M.A. (1998). A superfamily of proteins that contain the cold-shock domain. Trends Biochem. Sci. 23, 286-290.
25. GRIFFITH, T.S., MOORE, J., and VAN OOSTEN, R. (2004). The histone deacetylase inhibitor depsipeptide (FR901228) enhances the cytotoxic activity of Ad5-TRAIL against human prostate tumor cells. Mol. Ther. 1(Suppl. 9), 361-362.
26. GRILL, J., VAN BEUSECHEM, V.W., VAN DER VALK, P., DIRVEN, C.M., LEONHART, A., PHERAI, D.S., HAISMA, H.J., PINEDO, H.M., CURIEL, D.T., and GERRITSEN, W.R. (2001). Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids. Clin. Cancer Res. 7, 641-650.
27. HALBERT, D.N., CUTT, J.R., and SHENK, T. (1995). Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression and host cell shutoff. J. Virol. 56, 250-257.
28. HALEY, K.P., OVERHAUSER, J., BABISS, L.E., GINSBERG, H.S., and JONES, N.C. (1984). Transformation properties of type 5 adenovirus mutants that differentially express the E1A gene products. Proc. Natl. Acad. Sci. U.S.A. 81, 5734-5738.
29. HALLENBECK, P.L., CHANG, Y.N., HAY, C., GOLIGHTLY, D., STEWART, D., LIN, J., PHIPPS, S., and CHIANG, Y.L. (1999). A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum. Gene Ther. 10, 1721-1733.
30. HEISE, C., SAMPSON-JOHANNES, A., WILLIAMS, A., McCORMICK, F., VON HOFF, D.D., and KIRN, D.H. (1997). ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3, 639-645.
31. HO, D.M., HSU, C.Y., TING, L.T., and CHIANG, H. (2003). MIB-1 and DNA topoisomerase II α could be helpful for predicting long-term survival of patients with glioblastoma. Am. J. Clin. Pathol. 119, 715-722.
32. HOLM, P.S., BERGMANN, S., JURCHOTT, K., LAGE, H., BRAND, K., LADHOFF, A., MANTWILL, K., CURIEL, D.T., DOBBELSTEIN, M., DIETEL, M., GANSBACHER, B., and ROYER, H.D. (2002). YB-1 relocates to the nucleus in adenovirus-infected cells and facilitates viral replication by inducing E2 gene expression through the E2 late promoter. J. Biol. Chem. 277, 10427-10434.
33. HOLM, P.S., LAGE, H., BERGMANN, S., JURCHOTT, K., GLOCKZIN, G., BERNSHAUSEN, A., MANTWILL, K., LADHOFF, A., WICHERT, A., MYMRYK, J.S., RITTER, T., DIETEL, M., GANSBACHER, B., and ROYER, H.D. (2004). Multidrug-resistant cancer cells facilitate E1-independent adenoviral replication: Impact for cancer gene therapy. Cancer Res. 64, 322-328.
34. ISE, T., NAGATANI, G., IMAMURA, T., KATO, K., TAKANO, H., NOMOTO, M., IZUMI, H., OHMORI, H., OKAMOTO, T., OHGA, T., UCHIUMI, T., KUWANO, M., and KOHNO, K. (1999). Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. Cancer Res. 59, 342-346.
35. IZUMI, H., IMAMURA, T., NAGATANI, G., ISE, T., MURAKAMI, T., URAMOTO, H., TORIGOE, T., ISHIGUCHI, H., YOSHIDA, Y., NOMOTO, M., OKAMOTO, T., UCHIUMI, T., KUWANO, M., FUNA, K., and KOHNO, K. (2001). Y box-binding protein-1 binds preferentially to single-stranded nucleic acids and exhibits 3′ → 5′ exonuclease activity. Nucleic Acids Res. 29, 1200-1207.
36. JANZ, M., HARBECK, N., DETTMAR, P., BERGER, U., SCHMIDT, A., JURCHOTT, K., SCHMITT, M., and ROYER, H.D. (2002). Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int. J. Cancer 97, 278-282.
37. JOUNAIDI, Y., and WAXMAN, D.J. (2004). Use of replication-conditional adenovirus as a helper system to enhance delivery of P450 prodrug-activation genes for cancer therapy. Cancer Res. 64, 292-303.
38. KAMURA, T., YAHATA, H., AMADA, S., OGAWA, S., SONODA, T., KOBAYASHI, H., MITSUMOTO, M., KOHNO, K., KUWANO, M., and NAKANO, H. (1999). Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma? Cancer 85, 2450-2454.
39. KAUFFMANN, H.M., VORDERSTEMANN, B., and SCHRENK, D. (2001). Basal expression of the rat, but not of the human, multidrug resistance protein 2 (MRP2) gene is mediated by CBF/NF-Y and Sp1 promoter-binding sites. Toxicology 167, 25-35.
40. KELLY, P.J., DAUMAS-DUPORT, C., KISPERT, D.B., KALL, B.A., SCHEITHAUER, B.W., and ILLIG, J.J. (1987). Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J. Neurosurg. 66, 865-874.
41. KHURI, F.R., NEMUNAITIS, J., GANLY, I., ARSENEAU, J., TANNOCK, I.F., ROMEL, L., GORE, M., IRONSIDE, J., MACDOUGALL, R.H., HEISE, C., RANDLEV, B., GILLENWATER, A.M., BRUSO, P., KAYE, S.B., HONG, W.K., and KIRN, D.H. (2000). A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6, 879-885.
42. KIM, M.S., BLAKE, M., BAEK, J.H., KOHLHAGEN, G., POMMIER, Y., and CARRIER, F. (2003). Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 63, 7291-7300.
43. KITAZONO, M., GOLDSMITH, M.E., AIKOU, T., BATES, S., and FOJO, T. (2001). Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228. Cancer Res. 61, 6328-6330.
44. KOIKE, K., UCHIUMI, T., OHGA, T., TOH, S., WADA, M., KOHNO, K., and KUWANO, M. (1997). Nuclear translocation of the Y-box binding protein by ultraviolet irradiation. FEBS Lett. 417, 390-394.
45. KOIZUMI, N., HATANO, E., NITTA, T., TADA, M., HARADA, N., TAURA, K., IKAI, I., and SHIMAHARA, Y. (2005). Blocking of PI3K/Akt pathway enhances apoptosis induced by SN-38, an active form of CPT-11, in human hepatoma cells. Int. J. Oncol. 26, 1301-1306.
46. KONDO, S., KONDO, Y., HARA, H., KAAKAJI, R., PETERSON, J.W., MORIMURA, T., TAKEUCHI, J., and BARNETT, G.H. (1996). mdm2 gene mediates the expression of mdr1 gene and P-glycoprotein in a human glioblastoma cell line. Br. J. Cancer 74, 1263-1268.
47. LADOMERY, M., and SOMMERVILLE, J. (1995). A role for Y-box proteins in cell proliferation. Bioessays 17, 9-11.
48. LAMFERS, M.L., GRILL, J., DIRVEN, C.M., VAN BEUSECHEM, V.W., GEOERGER, B., VAN DEN BERG, J., ALEMANY, R., FUEYO, J., CURIEL, D.T., VASSAL, G., PINEDO, H.M., VANDERTOP, W.P., and GERRITSEN, W.R. (2002). Potential of the conditionally replicative adenovirus Ad5-Δ24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res. 62, 5736-5742.
49. LASHAM, A., LINDRIDGE, E., RUDERT, F., ONRUST, R., and WATSON, J. (2000). Regulation of the human fas promoter by YB-1, Purα and AP-1 transcription factors. Gene 252, 1-13.
50. LENNETTE, E.H. (1969). General principles underlying laboratory diagnosis of viral and rickettsial infections. In: Lennette, E.H., and Schmidt, N.J., eds. Diagnostic Procedures for Viral and Rickettsial Infections. (American Public Health Association, New York) pp. 1-63.
51. LEVENSON, V.V., DAVIDOVICH, I.A., and RONINSON, I.B. (2000). Pleiotropic resistance to DNA-interactive drugs is associated with increased expression of genes involved in DNA replication, repair, and stress response. Cancer Res. 60, 5027-5030.
52. MARENSTEIN, D.R., OCAMPO, M.T., CHAN, M.K., ALTAMIRANO, A., BASU, A.K., BOORSTEIN, R.J., CUNNINGHAM, R.P., and TEEBOR, G.W. (2001). Stimulation of human endonuclease III by Y box-binding protein 1 (DNA-binding protein B). Interaction between a base excision repair enzyme and a transcription factor. J. Biol. Chem. 276, 21242-21249.
53. MASSEY, V., and WALLNER, K.E. (1990). Patterns of second recurrence of malignant astrocytomas. Int. J. Radiat. Oncol. Biol. Phys. 18, 395-398.
54. MATSUMOTO, K., and WOLFFE, A.P. (1998). Gene regulation by Y-box proteins: Coupling control of transcription and translation. Trends Cell Biol. 8, 318-323.
55. MOHAMMADI, E.S., KETNER, E.A., JOHNS, D.C., and KETNER, G. (2004). Expression of the adenovirus E4 34K oncoprotein inhibits repair of double strand breaks in the cellular genome of a 293-based inducible cell line. Nucleic Acids Res. 32, 2652-2659.
56. NEVINS, J.R. (1981). Mechanism of activation of early viral transcription by the adenovirus E1A gene product. Cell 26, 213-220.
57. ODA, Y., SAKAMOTO, A., SHINOHARA, N., OHGA, T., UCHIUMI, T., KOHNO, K., TSUNEYOSHI, M., KUWANO, M., and IWAMOTO, Y. (1998). Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma. Clin. Cancer Res. 4, 2273-2277.
58. ODA, Y., OHISHI, Y., SAITO, T., HINOSHITA, E., UCHIUMI, T., KINUKAWA, N., IWAMOTO, Y., KOHNO, K., KUWANO, M., and TSUNEYOSHI, M. (2003). Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase II α expression, and with poor prognosis in synovial sarcoma. J. Pathol. 199, 251-258.
59. OHGA, T., KOIKE, K., ONO, M., MAKINO, Y., ITAGAKI, Y., TANIMOTO, M., KUWANO, M., and KOHNO, K. (1996). Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res. 56, 4224-4228.
60. OHGA, T., UCHIUMI, T., MAKINO, Y., KOIKE, K., WADA, M., KUWANO, M., and KOHNO, K. (1998). Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J. Biol. Chem. 273, 5997-6000.
61. OKAMOTO, T., IZUMI, H., IMAMURA, T., TAKANO, H., ISE, T., UCHIUMI, T., KUWANO, M., and KOHNO, K. (2000). Direct interaction of p53 with the Y-box binding protein, YB-1: a mechanism for regulation of human gene expression. Oncogene 19, 6194-6202.
62. OOSTERHOFF, D., VAN BEUSECHEM, V.W., BOVEN, E., PINEDO, H.M., and GERRITSEN, W.R. (2004). Synergism between a conditionally replicating adenovirus expressing p53 and oxaliplatin in the antiproliferative effects on human colon cancer cell lines. Mol. Ther. 9(Suppl. 1), 110.
63. v Integrins as receptors for tumor targeting by circulating ligands. Nat. Biotechnol. 15, 542-546.
64. PERRICAUDET, M., AKUSJARVI, G., VIRTANEN, A., and PETTERSSON, U. (1979). Structure of two spliced mRNAs from the transforming region of human subgroup C adenoviruses. Nature 281, 694-696.
65. PONG, R.C., LAI, Y.J., CHEN, H., OKEGAWA, T., FRENKEL, E., SAGALOWSKY, A., and HSIEH, J.T. (2003). Epigenetic regulation of coxsackie and adenovirus receptor (CAR) gene promoter in urogenital cancer cells. Cancer Res. 63, 8680-8686.
66. QIAN, D.Z., WANG, X., KACHHAP, S.K., KATO, Y., WIE, Y., ZHANG, L., ATADJA, P., and PILI, R. (2004). The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/222584. Cancer Res. 64, 6626-6634.
67. SACHS, M.D., RAMAMURTHY, M., POEL, H., WICKHAM, T.J., LAMFERS, M., GERRITSEN, W., CHOWDHURY, W., LI, Y., SCHOENBERG, M.P., and RODRIGUEZ, R. (2004). Histone deacetylase inhibitors upregulate expression of the coxsackie-adenovirus receptor (CAR) preferentially in bladder cancer cells. Cancer Gene Ther. 11, 477-486.
68. SCHAACK, J., SCHEDL, P., and SHENK, T. (1990). Topoisomerase I and II cleavage of adenovirus DNA in vivo: Both topoisomerase activities appear to be required for adenovirus DNA replication. J. Virol. 64, 78-85.
69. SHIBAHARA, K., SUGIO, K., OSAKI, T., UCHIUMI, T., MAEHARA, Y., KOHNO, K., YASUMOTO, K., SUGIMACHI, K., and KUWANO, M. (2001). Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin. Cancer Res. 7, 3151-3155.
70. SHIBAO, K., TAKANO, H., NAKAYAMA, Y., OKAZAKI, K., NAGATA, N., IZUMI, H., UCHIUMI, T., KUWANO, M., KOHNO, K., and ITOH, H. (1999). Enhanced coexpression of YB-1 and DNA topoisomerase II alpha genes in human colorectal carcinomas. Int. J. Cancer 83, 732-737.
71. SOMMERVILLE, J. (1999). Activities of cold-shock domain proteins in translation control. Bioessays 21, 319-325.
72. STEIN, U., JURCHOTT, K., WALTHER, W., BERGMANN, S., SCHLAG, P.M., and ROYER, H.D. (2001). Hyperthermia-induced nuclear translocation of transcription factor YB-1 leads to enhanced expression of multidrug resistance-related ABC transporters. J. Biol. Chem. 276, 28562-28569.
73. STEINWAERDER, D.S., CARLSON, C.A., and LIEBER, A. (2000). DNA replication of first-generation adenovirus vectors in tumor cells. Hum. Gene Ther. 11, 1933-1948.
74. SUTHERLAND, B.W., KUCAB, J., WU, J., LEE, C., CHEANG, M.C., YORIDA, E., TURBIN, D., DEDHAR, S., NELSON, C., POLLAK, M., LEIGHTON GRIMES, H., MILLER, K., BADVE, S., HUNTSMAN, D., BLAKE-GILKS, C., CHEN, M., PALLEN, C.J., and DUNN, S.E. (2005). Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 24, 4281-4292.
75. TEWS, D.S., NISSEN, A., KULGEN, C., and GAUMANN, A.K. (2000). Drug resistance-associated factors in primary and secondary glioblastomas and their precursor tumors. J. Neurooncol. 50, 227-237.
76. WALLNER, K.E., GALICICH, J.H., KROL, G., ARBIT, E., and MALKIN, M.G. (1989). Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int. J. Radiat. Oncol. Biol. Phys. 16, 1405-1409.
77. WICKHAM, T.J., TZENG, E., SHEARS, L.L.N., ROELVINK, P.W., LI, Y., LEE, G.M., BROUGH, D.E., LIZONOVA, A.A., and KOVESDI, I. (1997). Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J. Virol. 71, 8221-8229.
78. WILDNER, O., BLAESE, R.M., and MORRIS, J.C. (1999). Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res. 59, 410-413.
79. WOLFFE, A.P. (1994). Structural and functional properties of the evolutionarily ancient Y-box family of nucleic acid binding proteins. Bioessays 16, 245-251.
80. WOLFFE, A.P., TAFURI, S., RANJAN, M., and FAMILARI, M. (1992). The Y-box factors: A family of nucleic acid binding proteins conserved from Escherichia coli to man. New Biol. 4, 290-298.
81. WONG, M.L., and HSU, M.T. (1990). Involvement of topoisomerases in replication, transcription, and packaging of the linear adenovirus genome. J. Virol. 64, 691-699.
82. YAHATA, H., KOBAYASHI, H., KAMURA, T., AMADA, S., HIRAKAWA, T., KOHNO, K., KUWANO, M., and NAKANO, H. (2002). Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer. J. Cancer Res. Clin. Oncol. 128, 621-626.
83. YOU, L., YANG, C.T., and JABLONS, D.M. (2000). ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. Cancer Res. 60, 1009-1013.
84. YU, D.C., CHEN, Y., DILLEY, J., LI, Y., EMBRY, M., ZHANG, H., NGUYEN, N., AMIN, P., OH, J., and HENDERSON, D.R. (2001). Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res. 61, 517-525.